Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Haude

Showing results (151-160 of 208) with videos related to

Pageof 21
Sort By:
European Heart Journal|October 12, 2017
Report of an ESC-EAPCI Task Force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: executive summaryRobert A Byrne, Giulio G Stefanini, Davide Capodanno, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|August 7, 2018
Safety and clinical performance of a drug eluting absorbable metal scaffold in the treatment of subjects with de novo lesions in native coronary arteries: Pooled 12-month outcomes of BIOSOLVE-II and BIOSOLVE-IIIMichael Haude, Hüseyin Ince, Stephan Kische, et al.
International Journal of Cardiology|January 3, 2018
In vivo serial invasive imaging of the second-generation drug-eluting absorbable metal scaffold (Magmaris - DREAMS 2G) in de novo coronary lesions: Insights from the BIOSOLVE-II First-In-Man TrialHector M Garcia-Garcia, Michael Haude, Kayode Kuku, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|May 20, 2025
Clinical outcomes of the third-generation resorbable magnesium scaffold for coronary artery lesions: three-year results of the BIOMAG-I studyMichael Haude, Adrian Wlodarczak, René J van der Schaaf, et al.
European Heart Journal. Acute Cardiovascular Care|March 16, 2018
Guideline-adherence regarding critical time intervals in the German Chest Pain Unit registryMehrshad Vafaie, Matthias Hochadel, Thomas Münzel, et al.
JACC. Cardiovascular Interventions|May 26, 2009
Early- and long-term intravascular ultrasound and angiographic findings after bioabsorbable magnesium stent implantation in human coronary arteriesRon Waksman, Raimund Erbel, Carlo Di Mario, et al.
The American Journal of Cardiology|January 27, 2019
Serial 3-Dimensional Optical Coherence Tomography Assessment of Jailed Side-Branch by Second-Generation Drug-Eluting Absorbable Metal Scaffold (from the BIOSOLVE-II Trial)Yuichi Ozaki, Hector M Garcia-Garcia, Alexandre Hideo-Kajita, et al.
European Journal of Heart Failure|May 23, 2012
Treatment of functional mitral regurgitation by percutaneous annuloplasty: results of the TITAN TrialTomasz Siminiak, Justina C Wu, Michael Haude, et al.
Lancet (London, England)|June 5, 2007
Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trialRaimund Erbel, Carlo Di Mario, Jozef Bartunek, et al.
Cardiovascular Revascularization Medicine : Including Molecular Interventions|August 8, 2021
Sustained Safety and Performance of a Second-Generation Sirolimus-Eluting Absorbable Metal Scaffold: Long-Term Data of the BIOSOLVE-II First-in-Man Trial at 5 YearsMichael Haude, Ralph Toelg, Pedro Alves Lemos, et al.
Pageof 21

Showing results (151-160 of 208) with videos related to

Sort By:
Pageof 21
European Heart Journal|October 12, 2017
Report of an ESC-EAPCI Task Force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: executive summaryRobert A Byrne, Giulio G Stefanini, Davide Capodanno, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|August 7, 2018
Safety and clinical performance of a drug eluting absorbable metal scaffold in the treatment of subjects with de novo lesions in native coronary arteries: Pooled 12-month outcomes of BIOSOLVE-II and BIOSOLVE-IIIMichael Haude, Hüseyin Ince, Stephan Kische, et al.
International Journal of Cardiology|January 3, 2018
In vivo serial invasive imaging of the second-generation drug-eluting absorbable metal scaffold (Magmaris - DREAMS 2G) in de novo coronary lesions: Insights from the BIOSOLVE-II First-In-Man TrialHector M Garcia-Garcia, Michael Haude, Kayode Kuku, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|May 20, 2025
Clinical outcomes of the third-generation resorbable magnesium scaffold for coronary artery lesions: three-year results of the BIOMAG-I studyMichael Haude, Adrian Wlodarczak, René J van der Schaaf, et al.
European Heart Journal. Acute Cardiovascular Care|March 16, 2018
Guideline-adherence regarding critical time intervals in the German Chest Pain Unit registryMehrshad Vafaie, Matthias Hochadel, Thomas Münzel, et al.
JACC. Cardiovascular Interventions|May 26, 2009
Early- and long-term intravascular ultrasound and angiographic findings after bioabsorbable magnesium stent implantation in human coronary arteriesRon Waksman, Raimund Erbel, Carlo Di Mario, et al.
The American Journal of Cardiology|January 27, 2019
Serial 3-Dimensional Optical Coherence Tomography Assessment of Jailed Side-Branch by Second-Generation Drug-Eluting Absorbable Metal Scaffold (from the BIOSOLVE-II Trial)Yuichi Ozaki, Hector M Garcia-Garcia, Alexandre Hideo-Kajita, et al.
European Journal of Heart Failure|May 23, 2012
Treatment of functional mitral regurgitation by percutaneous annuloplasty: results of the TITAN TrialTomasz Siminiak, Justina C Wu, Michael Haude, et al.
Lancet (London, England)|June 5, 2007
Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trialRaimund Erbel, Carlo Di Mario, Jozef Bartunek, et al.
Cardiovascular Revascularization Medicine : Including Molecular Interventions|August 8, 2021
Sustained Safety and Performance of a Second-Generation Sirolimus-Eluting Absorbable Metal Scaffold: Long-Term Data of the BIOSOLVE-II First-in-Man Trial at 5 YearsMichael Haude, Ralph Toelg, Pedro Alves Lemos, et al.
Pageof 21